Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma

Table 3 Toxicities after mobilization in 39 patients with high-risk non-Hodgkin’s lymphoma

Parameter	R-CHOP (n = 14)	CHOP (n = 25)	P value
Time from mobilization to the nadir of WBC (days)^a	12 (9–14)	11 (0–16)	0.104
WBC count at nadir (×10⁹/L)^a	1.24 (0.23–2.60)	1.30 (0.06–3.70)	0.856
Time from mobilization to the nadir of neutrophils (days)^a	12.5 (9–15)	11 (5–15)	0.042
Neutrophil count at nadir (×10⁹/L)^a	0.46 (0–1.60)	0.50 (0–2.41)	0.915
Time from mobilization to the nadir of PLT (days)^a	14.5 (11–19)	13.0 (6–16)	0.008
PLT count at nadir (×10⁹/L)^a	97.5 (51–171)	97.0 (12–193)	0.797
PLT transfusions [cases (%)]	1 (7.1)	2 (8.0)	0.748
Vomiting [cases (%)]			0.805
Grade 1/2	8 (57.1)	18 (72.0)
Grade 3	1 (7.1)	2 (8.0)
Febrile neutropenia [cases (%)]	3 (21.4)	9 (36.0)	0.477
Diarrhea [cases (%)]	0	4 (16.0)	0.387
ALT elevation [cases (%)]	5 (35.7)	15 (60.0)	0.234
Anemia [cases (%)]			0.212
Grade 1/2	7 (50.0)	20 (80.0)
Grade 3	1 (7.1)	1 (4.0)

PLT platelets, ALT alanine transaminase. Other abbreviations as in Tables 1 and 2
^aThe values are presented as median followed by range in parentheses; other values are presented as the number of patients followed by percentages in parentheses

ISSN: 2523-3548